EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to o...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-06, Vol.12, p.634416-634416
Main Authors: Luft, Thomas, Wendtner, Clemens-Martin, Kosely, Florentina, Radujkovic, Aleksandar, Benner, Axel, Korell, Felix, Kihm, Lars, Bauer, Matthias F, Dreger, Peter, Merle, Uta
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
angiopoietin-2 (Ang-2)
Biomarkers - metabolism
COVID-19 - diagnosis
COVID-19 - mortality
EASIX
endothelial activation and stress index
Endothelial Cells - physiology
Female
Hematopoietic Stem Cell Transplantation
Hospitalization
Humans
Immunology
Male
Middle Aged
Prognosis
Prospective Studies
Respiration, Artificial
SARS-CoV-2 - physiology
SARS-CoV2 (COVID- 19)
Severity of Illness Index
soluble thrombomodulin
suppressor of tumorigenicity 2 (ST2)
Survival Analysis
Transplantation, Homologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions. EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.634416